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ABSTRACT 10 
Benzo[a]pyrene (B[a]P) is a known human carcinogen and is commonly used as a surrogate for assessing the 11 
carcinogenic risk posed by complex mixtures of polycyclic aromatic hydrocarbons (PAHs) present in air particulate 12 
matter (PM). However, studies have shown that using B[a]P as a surrogate may underestimate the carcinogenic 13 
potential of PAH mixtures, as the risk assessment approach does not consider interaction effects. Thus, toxicological 14 
studies using B[a]P to assess its carcinogenic potential in environmentally derived complex mixtures, as opposed to 15 
single compound experiments, could improve risk assessment. The intention of the present study was to develop an 16 
online HPLC fractionation system for the selective removal of B[a]P from air PM extracts. Two serial pyrenylethyl 17 
(PYE) columns enabled selective separation of B[a]P from its isomers and other PAHs as well as a short 18 
fractionation cycle of 30 minutes. One run consisted of three collection steps: the first fraction contained PAHs 19 
eluting earlier than B[a]P, the second contained B[a]P and the last contained later-eluting PAHs. The selectivity and 20 
recovery of the system was investigated using extracts of Stockholm air PM samples. The overall recovery for all 21 
PAHs was approximately 80%, and the system proved to be selective, as it removed 94% of B[a]P and less than 3% 22 
of benzo[b]fluoranthene from the complex PAH mixture. Exposing human cells to blanks generated by the 23 
fractionation system did not induce cytotoxicity or DNA damage signalling. In conclusion, the online HPLC system 24 
was selective for B[a]P fractionation whilst minimising run-to-run variation and allowing repeated fractionations for 25 
larger samples due to its relatively short run time 26 
Keywords: automation, benzo[a]pyrene, fractionation, PAH, pyrenylethyl, synergism 27 
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1. Introduction 29 
 2 
Benzo[a]pyrene (B[a]P) belongs to the group of chemical compounds referred to as polycyclic aromatic 30 
hydrocarbons (PAHs) [1]. Recent studies on B[a]P have revealed its potential role as a cancer inducer in human skin 31 
breast cells, and neurotoxic effects resulting from exposure to B[a]P have been investigated in Sprague-Dawley rat 32 
[2-4]. 33 
B[a]P is currently the only PAH classified as carcinogenic to humans, whilst other PAHs, such as 34 
dibenz[a,h]anthracene, several dibenzopyrenes and benzofluoranthenes, have been classified as “probably or 35 
possibly carcinogenic to humans” based on studies using various in vitro and in vivo experimental models [1]. B[a]P 36 
is the key compound used in the two main approaches for assessing the carcinogenic risk of human exposure to 37 
PAHs in ambient air [5,6]. In the epidemiological approach, B[a]P is used as a surrogate for the entire complex 38 
mixture of PAHs together with occupational epidemiological data to determine quantitative risk estimates. The 39 
World Health Organisation has derived a unit risk value based on the increased risk for lung cancer in coke-oven 40 
workers [7,8]. However, a major weakness of this methodology is that it assumes that the relative PAH 41 
concentration profiles are stable between different exposure situations. The other method for risk assessment utilises 42 
animal experiment data on the carcinogenic potency of individual PAHs relative to that of B[a]P. These relative 43 
potency values, referred to as toxic equivalency factors (TEFs) or potency equivalency factors (PEFs), are then 44 
multiplied with the concentration of the respective PAH, creating a product called a B[a]P equivalent [5]. Summing 45 
the B[a]P equivalents and multiplying by the potency of B[a]P gives a risk estimate [5]. One major assumption 46 
using the TEF/PEF scheme is the additivity of individual risks, implying that interactions among the different PAHs 47 
in complex exposure situations do not modulate the carcinogenic potential of the PAH mixture. Chemical 48 
interactions can be additive, synergistic, potentiative or antagonistic when two or more chemicals are combined. 49 
That is, the toxicity of a PAH mixture can increase or decrease depending on the corresponding interactions, which 50 
can lead to under- or overestimations of its toxicological effect [9]. Previous studies have reported synergistic [10-51 
15] and antagonistic effects [16-18] of complex PAH mixtures in different biological systems, and the risk of 52 
underestimating the carcinogenic potential by the use of TEFs/PEFs has been demonstrated in several in vitro and in 53 
vivo studies [10-12,14,19,20]. Moreover, a newer approach to environmental cancer research, in which synergistic 54 
effects are included as one of the factors in the study of mixtures, has been proposed by the US President’s Cancer 55 
Panel [21]. As a result, testing the toxicity of chemical mixtures or environmental samples has been increasing in 56 
comparison to using a single compound [21]. 57 
Sample preparation methods for toxicity testing are crucial, and various fractionation methods have been established 58 
to obtain cleaner and more defined fractions. Most of the techniques involve initial crude and subsequent fine 59 
fractionations, followed by chemical analysis. These methods have several different names, including bioassay-60 
directed chemical analysis [22], bioassay-directed fractionation [23-26], toxicity-based fractionation [27] and effect-61 
directed fractionation [28]. Previous studies have been conducted using a similar procedure. First, sample extracts 62 
were treated with silica gel or cleaned up with solid phase extraction (SPE). Then the eluates were subjected to 63 
liquid chromatography (LC) to obtain refined fractions and sub-fractions, if further separation was necessary. Then, 64 
an aliquot was analysed for chemical content using high performance LC with ultra-violet and/or fluorescence 65 
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detection (HPLC-UV/FLD), or gas chromatography/mass spectrometry (GC/MS), while another aliquot was 66 
designated for toxicity tests [22-30]. Other studies have been conducted using solvent extraction methods with 67 
various combinations of organic solvents, or by SPE using different eluting conditions [31,32]. Additionally, an 68 
automated normal-phase LC (NPLC) fractionation system for PAHs in sediments using three LC columns was 69 
presented by Varel et al. [33]. 70 
Despite high-resolution fractionation steps, the final solution is often a mixture of several compounds with similar 71 
chemical properties. As a result, further investigations are required to narrow the candidates and identify the main 72 
compounds contributing to toxicological effects. Of the various chromatographic techniques used for selective 73 
fractionation, HPLC is considered to be a good tool, especially when appropriate HPLC columns are used to 74 
maximise the separation efficiency. Silica-based columns modified with amino, nitro, cyano, alkylhydroxy, 75 
alkylamino and alkylcyano moiety have been used for PAH analysis to remove aliphatic hydrocarbons and 76 
fractionate PAHs, based on the number of aromatic rings [34-37]. Polymeric C18 columns were found to have unique 77 
selectivity for PAHs and a reversed-phase LC (RPLC) with FLD has replaced traditional NPLC for both preparative 78 
and quantitative PAH analysis [38-41]. Polymeric C18 columns selectively retain isomeric PAHs, as explained in the 79 
“slot model” in which PAH retention is highly dependent on the molecular shape of the PAHs, that is, their ability to 80 
fit in the slit-like holes of the stationary phase [42]. However, fractions from an RPLC system normally contain 81 
water, which hinders fast evaporation during the preparation of samples for toxicity tests. 82 
The ability to investigate the effects of interactions between B[a]P and other compounds in complex mixtures by 83 
selective inclusion/exclusion would be of significant benefit for future toxicity analyses. Thus, the aim of the present 84 
study was to develop an NPLC system for B[a]P-specific fractionation. The online system was equipped with an 85 
autosampler and switching valves controlled by a computer for precise and reproducible fractionation. The system 86 
was optimised using PAH standards and finally evaluated for separation efficiency and recoveries using a complex 87 
PAH mixture extracted from air particulate matter (PM) collected from the urban atmosphere of Stockholm. 88 
 89 
2. Materials and methods 90 
2.1 Chemicals and reagents 91 
Solvents used for extraction, sample preparation and analysis were hexane, acetone and toluene (HPLC grade, 92 
Walkerburn Scotland) and dodecane (anhydrous, ≥99%, Sigma-Aldrich, St. Louis, MO, USA). All PAH standards 93 
and internal standards (ISs) used in the present study are specified with their abbreviation, CAS number, supplier, 94 
purity, molecular formula and molecular weight in the Supplementary data (S) Table S1. 95 
2.2 Air sampling 96 
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Air PM was collected at the rooftop level (22 metres from the ground) of the Arrhenius building at Stockholm 97 
University [43]. Sampling was performed on a fluorocarbon coated glass fibre filter (Ø = 235 mm, Fiberfilm Filters, 98 
Pallflex, Pall Corporation, Putnam, CT, USA) using an in-house constructed pump device equipped with a flow 99 
meter. The filter was desiccated for at least 24 hours before and after sampling, wrapped in aluminium foil and 100 
stored at -20 ºC until extraction. The total volume of sampled air was 5141 m
3
, and the average sampling rate was 101 
72.5 m
3
/hr. The sampling was performed in January 2013 (January 18-21) to avoid possible pollen introduction. 102 
2.3 Extraction and SPE clean-up 103 
The sampled filter was extracted with toluene for 5 × 30 min using pressurised liquid extraction (ASE 200 104 
Accelerated Solvent Extraction System, Dionex Co., Sunnyvale, CA, USA). Then, 0.6 mL of the extract, 105 
corresponding to 56 m
3
, was applied to a silica SPE column (100 mg, IST Isolute, Biotage, Cardiff, UK) and eluted 106 
with 2 mL of hexane to remove polar compounds and obtain a PAH enriched fraction. The final hexane eluate was 107 
gently evaporated to 20-50 µL under a nitrogen stream before online HPLC fractionation. The extraction and SPE 108 
clean-up procedures are described in detail elsewhere [44]. 109 
2.4 Online HPLC fractionation system 110 
A schematic illustration of the automated system for B[a]P-specific fractionation is shown in Fig. S1. 111 
The chromatographic system comprised an HPLC pump (Varian 9001, Varian Inc., Palo Alto, CA, USA), an 112 
autosampler (CMA/240, CMA Microdialysis AB, Stockholm, Sweden), two 2-(1-pyrenyl)ethyl (PYE) columns 113 
(Cosmosil PYE, 150 × 4.6 mm, 5 µm,  Nacalai Tesque Inc., Kyoto, Japan) and a UV detector (Varian 9050, Varian 114 
Inc., Palo Alto, CA, USA). In addition, two position-switching valves with 3 (valve 2 and 3) and 4 (valve 1) ports 115 
(Valco Instruments Co. Inc., Houston, TX, USA) were used to change the column flow and collect the fractions into 116 
appointed test tubes. The autosampler was controlled with the CMA/200 v2.02 software (CMA Microdialysis AB, 117 
Stockholm, Sweden) and all hardware communications, including sample injection, valve switching and monitoring 118 
of the UV signal, were regulated by a personal computer equipped with the ELDS Win v1.1 software 119 
(Chromatography Data Systems AB, Svartsjö, Sweden). The temperature of the columns was set to 30 ºC with a 120 
column oven (Croco-cil, Cluzeau Info Labo, Sainte-Foy-La-Grande, France) during operation to minimise run-to-121 
run retention time variation. 122 
2.5 LC-GC/MS analysis 123 
The collected fractions were spiked with ISs and the volume was reduced to 100 µL under a gentle stream of 124 
nitrogen. Then, the samples were transferred to micro vials for LC-GC/MS analysis. Analytical parameters are 125 
described in detail elsewhere [45]. 126 
 127 
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3. Results and discussion 128 
3.1 LC column selection 129 
A test solution in hexane was prepared by mixing B[a]P with six structural isomers commonly encountered in 130 
environmental samples: benzo[a]fluoranthene (B[a]F), benzo[b]fluoranthene (B[b]F), benzo[j]fluoranthene (B[j]F), 131 
benzo[k]fluoranthene  (B[k]F), benzo[e]pyrene (B[e]P) and perylene (Per). Initially, a nitrophenylpropyl (NO2) silica 132 
column (4.0 × 125 mm, 5 μm, Phenomenex, Torrance, CA, USA) was evaluated for the separation of the seven 133 
PAHs with molecular weights of 252 Da using hexane as the mobile phase. Hexane was selected as the mobile 134 
phase because it is a common solvent in NPLC systems and it has been recommended for increasing the resolution 135 
of PAHs [30]. However, insufficient separation was achieved using this set-up, and a PYE column was investigated 136 
to determine if it could improve the separation. Previously, this type of column has mainly been used for the 137 
separation of polychlorinated biphenyls (PCBs) and polychlorinated dibenzo-p-dioxins (PCDDs) [46-49]. Studies on 138 
PAH analysis using PYE columns are scarce, but this type of column was previously used in HPLC/UV analysis for 139 
the quantitation of PCBs and PAHs [50]. The retention of analytes on the PYE column is due to the donor-acceptor 140 
interaction in which the electron-rich pyrenyl group on the column function as electron donor to the analytes via π-π 141 
charge transfer, resulting in increased retention of planar analytes over non-planar ones owing to less steric 142 
hindrance [46]. The PYE column is also known to behave in the same manner as NO2 or NH2 substituted columns 143 
when used for PAH analysis in NPLC mode, that is, it separates PAHs based on their ring size but with less group 144 
separation efficiency than NO2 or NH2 substituted columns [51]. However, the PYE column is considered to be 145 
more suitable for isomer analysis [51]. Therefore, the PYE column was chosen in the present study because B[a]P 146 
separation from its isomers was the main issue rather than separation according to number of aromatic rings. The 147 
separation of the seven PAHs was improved and performed in a shorter time using the PYE column than with the 148 
NO2 column. However, B[a]P partially co-eluted with B[a]F and B[b]F as shown in Fig. 1, A. Peaks were identified 149 
by comparing the retention times obtained from the injection of individual PAHs. 150 
3.2 Serial column separation 151 
Based on the enhanced separation observed on the PYE column compared to the NO2 column, further exploration 152 
using the PYE column in the LC system was carried out to attempt to obtain baseline resolution of B[a]P from the 153 
other 252 Da molecular weight isomers. The peak capacity of an LC column is usually increased by the introduction 154 
of one or more columns into the existing set-up, either comprehensively or serially [52]. A serially coupled LC 155 
system is preferred compared to a comprehensive LC set-up because the peak capacity is greatly dependent on the 156 
orthogonality of the columns and requires relatively long separation times [52]. Previously reported studies have 157 
applied the serial column separation concept to complex samples of essential oils and digested proteins [53,54]. 158 
Accordingly, two PYE columns with the same dimensions were connected in series to reduce the co-elution of 159 
B[a]P with B[a]F and B[b]F. The separation of the seven 252 Da PAHs was enhanced using the PYE-PYE serial 160 
column set-up when compared to the system using one PYE column (Fig. 1, A and B). 161 
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3.3 The B[a]P-specific online HPLC fractionation system 162 
A UV chromatogram generated from injection of a standard solution containing 41 PAHs and 6 ISs in hexane on the 163 
automated B[a]P-specific online HPLC fractionation system is shown in Fig. 2 and depicts the time points for 164 
collection of the different fractions. B[a]F and B[j]F were only used to prepare the test solution of the 252 Da PAHs 165 
and were not included in the standard PAH solution. 166 
The large peak at the beginning of the chromatogram (5 min) is from toluene, which was used as the solvent for 167 
preparing the PAH stock solution. Each fractionation step is described in Fig. S2, A-F, in which the flow paths are 168 
differently coloured. The red line indicates the column flow before the backflush and the reversed column flow after 169 
the backflush is indicated with a blue line. 170 
The system began in standby mode, with the mobile phase flowing through the columns and valves into the waste 171 
bottle connected to valve V3 (Fig. S2, A). After injection, the system was put in standby mode for approximately six 172 
minutes to direct mobile phase and residual toluene to waste (W1), then valve V3 was switched to collect PAHs 173 
eluting earlier than B[a]P in fraction 1 (F1) (Fig. S2, B). Just before the elution of B[a]P, the system began 174 
collecting fraction 2 (F2) by diverting the flow through valve V2 (Fig. S2, C). 175 
Then, the column flow was reversed while valve V2 was kept at the same position to complete the collection of 176 
residual B[a]P in the tubing between the UV detector and the collecting tube (Fig. S2, D). Excess mobile phase was 177 
sent to the waste (W2) through valve V3 (Fig. S2, E), and then the backflush peak containing PAHs eluting later 178 
than B[a]P was collected in fraction 3 (F3) (Fig. S2, F). After finishing the collection, the system was returned to 179 
standby mode to prepare for the next run (Fig. S2, A). All valve switching times are presented in Table S2 and the 180 
run time for one total cycle of fractionation was 30 minutes. 181 
3.4 Fractionation of air PM extract 182 
SPE cleaned-up extracts of Stockholm air PM were fractionated on the system in triplicate. A chromatogram 183 
generated from an injection of a Stockholm air PM extract is presented in Fig. 3. 184 
Valve switching times for collecting F3 were adjusted to resolve peak broadening due to sample complexity. 185 
GC/MS chromatograms obtained in selected ion monitoring (SIM) mode, from which ions with m/z 252 were 186 
extracted to assess the separation selectivity of the B[a]P-specific online HPLC fractionation system (displayed in 187 
Fig. 4), are shown in Figs. S3, S4 and S5. The first fraction, F1 contained all four benzofluoranthenes but no 188 
detectable amount of B[a]P. A minor amount of B[b]F (2%) was present in fraction F2. B[e]P and Per peaks were 189 
observed in fraction F3, along with a small amount of B[a]P (6%). 190 
Waste was collected before F1 (W1) and between F2 and F3 (W2) (Fig. S6) to confirm that no PAHs were lost in 191 
the waste. Chromatograms of fractions from injections of a blank sample and hexane are shown in Figs. S7 and S8. 192 
Two system peaks were observed in GC/MS chromatograms from sample waste fractions and from the fractions 193 
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generated by blank and hexane injections. The system peaks did not interfere with other PAH peaks in the GC/MS 194 
chromatogram. GC/MS full scan spectra of the system peaks are shown in Fig. S9. A NIST library search found no 195 
relevant matches for these peaks, so another GC/MS system with different chromatographic conditions (Table S3) 196 
was used to analyse the eluate from the B[a]P-specific online HPLC fractionation system. Three major peaks were 197 
detected (Fig. S10) and matched with three different substituted pyrenes from the NIST library. The highest ranked 198 
hits for each peak were 1-hydroxypyrene, 1-pyrene-carboxaldehyde and 1-acetylpyrene, respectively. These 199 
compounds most likely originate from the pyrenyl moiety in the stationary phases of the HPLC columns (Fig. S11). 200 
In addition, no peaks were found in the GC/MS chromatograms when the eluate collected from the system without 201 
PYE columns was injected, which eliminates the injector, HPLC pump, valves and tubing as possible sources of the 202 
system peaks. 203 
3.5 Toxicological testing of chromatographic blanks 204 
The blank eluates generated from the fractionation system were applied to toxicity tests aimed at evaluating DNA 205 
damage signalling and cytotoxicity (methods are described in further detail in S7). Chk1 and H2AX are key signal 206 
transduction proteins activated by phosphorylation in response to DNA damage resulting from cellular exposure to 207 
PAHs [10]. The results of the present study showed no phosphorylation of Chk1 or H2AX in human HepG2 cells 208 
following exposure to the eluates whereas a 17- and 2-fold induction of Chk1 and H2AX, respectively, was 209 
observed in response to 3 µM B[a]P (Fig. S12, A-C). No effects were observed on the levels of p53 protein in any 210 
of the exposures (Fig. S12, A and D). Furthermore, no effects were observed on cell viability (Fig. S12, E). Taken 211 
together, these data demonstrate that the blank eluates generated from the fractionation system are non-cytotoxic to 212 
cells and do not induce DNA damage related-signalling. 213 
3.6 Recovery of PAHs and separation efficiency of B[a]P 214 
Quantitative PAH results are summarised in Fig. 5. Non-fractionated samples were prepared by spiking ISs into the 215 
SPE cleaned-up samples, while the collected fractions were spiked with ISs after the fractionation process. The 216 
average recovery of PAHs in the fractionation system was approximately 80%, varying from 61 to 105%. Main 217 
losses were due to residue remaining in the micro vial and injection needle. Therefore, the PAH concentrations of 218 
fractions generated on the B[a]P-specific online HPLC fractionation system should be re-analysed prior to 219 
toxicological tests to establish more accurate dose-responses. 220 
A relative comparison between different fractions was performed to investigate the separation efficiency of the 221 
B[a]P-specific online HPLC fractionation system. As shown in Fig. 6, 94% of B[a]P was found in F2 and 6% was 222 
found in F3, but no detectable amount was found in F1. The amount found in F3 could be explained by peak tailing 223 
of B[a]P on the LC columns, that is, a slight overlap with the following B[e]P peak. The standard deviations of the 224 
mean values of the relative amount were less than 1%. In the fractionation, the valve switching times were set such 225 
that greater than 90% of B[a]P could be collected while minimising the introduction of other PAHs in the same 226 
fraction. In addition, full scan GC/MS analysis of blank, non-fractionated and fractionated samples were conducted 227 
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in order to examine co-eluting compounds in the same region of chromatograms as the 252 Da PAHs (Fig. S13). 228 
Three unknown compounds (peak 5, 6 and 10) were detected in the chromatogram of the non-fractionated sample. 229 
Peak 6 and 10 could potentially be methylated isomers of 252 Da PAHs because their mass specta features a 230 
molecular ion at m/z 266. Peak 6 was also detected in F1, but no visible peaks were detected in F2 and F3 (Fig. S13, 231 
F1-F3). Methylated PAHs usually elute after the native PAHs on the PYE column in NPLC mode [55], but some 232 
methylated PAHs such as 1-methyl perylene elute earlier than their native forms [56]. Among possible methylated 233 
isomers, methylated B[a]Ps are of concern related to their mutagenicity [57-59] though they have been reported to 234 
be present at relatively low levels compared to that of B[a]P in coal tar [60]. On the assumption of peak 6 being one 235 
isomer of methylated B[a]P, its presence in F1 might contribute to the toxicity of the B[a]P-free fraction. However, 236 
the contribution to the toxicity is assumed to be low because the peak is relatively small. 237 
The PAH concentrations determined in the initial toluene extracts (Table S4) were comparable to those from a 238 
previous study conducted at the same sampling site [10]. The results of the present study demonstrated that the 239 
B[a]P-specific online HPLC fractionation system can selectively remove B[a]P from a complex Stockholm air PM 240 
extract. In addition, this system set-up can easily be modified by changing columns, mobile phase and valve 241 
switching times to selectively remove other PAHs of interest. 242 
 243 
4. Conclusions 244 
The present study established an online HPLC fractionation system for the selective removal of B[a]P from the 245 
complex PAH mixture of an air PM extract using two PYE columns in series. The system showed a high selectivity, 246 
removing 94% of B[a]P and less than 3% of B[b]F from the complex mixture. One fractionation cycle requires only 247 
30 minutes, which makes it possible to do repeated fractionations for larger samples. The system is simple and easy 248 
to re-construct in a normal chromatography lab, because it only requires analytical scale tubing, a pump, an injector, 249 
columns and a detector. More fractions can easily be obtained by adding additional switch valves or by introducing 250 
fraction collectors to the current system. In addition, automatic fractionation minimises the exposure of operators to 251 
toxicants and increases the precision and time efficiency. Sample overloading can be avoided by repeated 252 
fractionations and the system can be modified by changing mobile phase and columns, allowing for selective 253 
fractionation of other target compounds and matrices. The mixture as a whole or lacking B[a]P obtained from the 254 
system can assist in the evaluation of B[a]P toxicity by considering interactions between B[a]P and other co-existing 255 
compounds. Blanks generated on the fractionation system were not cytotoxic to cells and did not induce DNA 256 
damage-related signalling. In conclusion, this system is a useful tool for elucidating the toxicological effects of 257 
B[a]P in complex PAH mixtures. Furthermore, the mixture-based toxicity evaluation of not only B[a]P, but also 258 
other target compounds, could improve current methods for risk assessment. 259 
 260 
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Figure captions 351 
 352 
Fig. 1. HPLC/UV chromatogram of a PAH standard solution injected on (A) a PYE column and (B) a serial PYE 353 
column set-up. (A) Conditions: hexane 100%, flow rate 0.7 mL/min, ambient column temperature, UV detection at 354 
254 nm, (B) Conditions: hexane 100%, flow rate 0.8 mL/min, column temperature at 30 ºC, UV detection at 254 355 
nm. UV detector sensitivity of 0.02 absorbance units full scale (AUFS). AU: absorbance units. Ant*: Anthracene 356 
was added to the mixture as a retention indicator. 357 
Fig. 2. HPLC/UV chromatogram of the 41 PAH standard solution from the online HPLC fractionation system: (A) 358 
full-scale chromatogram, (B) enlarged chromatogram depicting fractionation points. Conditions: two PYE columns 359 
(150 × 4.6 mm, 5 µm), hexane 100%, flow rate 0.8 mL/min, column temperature at 30 ºC, UV detection at 254 nm, 360 
UV detector sensitivity of 0.02 AUFS. AU: absorbance units, F: fraction, W: waste. 361 
Fig. 3. HPLC/UV chromatogram of an injection of a Stockholm air PM extract on the B[a]P-specific online HPLC 362 
fractionation system. Instrumental conditions are described in Fig. 2. 363 
Fig. 4. GC/MS extracted ion chromatograms (m/z 252) of the fractions generated from an injection of a Stockholm 364 
air PM extract on the B[a]P-specific online HPLC fractionation system. 365 
Fig. 5. PAH concentrations determined in a Stockholm air PM extract and in the fractions collected from the B[a]P-366 
specific online HPLC fractionation system. Error bars show one standard deviation from the mean value (n = 3). 367 
Compound abbreviations are shown in Table S1. 368 
Fig. 6. Relative abundance of 252 Da molecular weight PAHs in the fractions generated by the B[a]P-specific online 369 
HPLC fractionation system. Error bars show one standard deviation from the mean value (n = 3). 370 
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Fig. 5. PAH concentrations determined in a Stockholm air PM extract and in the fractions collected from the B[a]P-
specific online HPLC fractionation system. Error bars show one standard deviation from the mean value (n = 3). 
Compound abbreviations are shown in Table S1. 
 
Fig. 6. Relative abundance of 252 Da molecular weight PAHs in the fractions generated by the B[a]P-specific online 
HPLC fractionation system. Error bars show one standard deviation from the mean value (n = 3). 
 1 
Supplementary data 1 
Benzo[a]pyrene-specific online HPLC fractionation of air particulate extracts – A tool for 2 
evaluating biological interactions 3 
Hwanmi Lim
a
, Christoffer Bergvall
a
, Ian Jarvis
b
, Åse Mattsson
b
, Kristian Dreij
b
, Ulla Stenius
b
, Roger Westerholm
a,
* 4 
a 
Department of Analytical Chemistry, Stockholm University, Svante Arrhenius väg 16 SE-106 91 Stockholm, 5 
Sweden 6 
b
 Institute of Environmental Medicine, Karonlinska Institutet, Box 210, SE-171 77 Stockholm, Sweden 7 
 8 
Contents 9 
S-1. List of PAH standards and internal standards 10 
S-2. Schematic illustration of the B[a]P-specific online HPLC fractionation system 11 
S-3. Valve positions during a run on the B[a]P-specific online HPLC fractionation system 12 
S-4. GC/MS chromatograms of Stockholm air PM extract from the B[a]P-specific online HPLC fractionation system 13 
S-5. GC/MS chromatograms of blank and hexane injections on the B[a]P-specific online HPLC fractionation system 14 
S-6. GC/MS full scan mass spectra of the system peaks from the B[a]P-specific online HPLC fractionation system 15 
S-7. Biological tests of eluates from the B[a]P-specific online HPLC fractionation system 16 
S-8. GC/MS full scan analysis of blank, non-fractionated and fractionated samples 17 
S-9. PAH concentrations in Stockholm air PM sample  18 
 2 
S-1. List of PAH standards and internal standards 19 
Table S1. List of PAH standards and surrogate internal standards with abbreviation, CAS Registry number, supplier, purity, molecular formula (M.f.) and 20 
molecular weight (M.w. in g/mol) 21 
Name Abbreviation CAS Registry No. Supplier 
Purity 
(%) 
M.f. M.w. 
Phenanthrene Phe 85-01-8 Merck, Germany 98.7 C14H10 178.23 
Anthracene Ant 120-12-7 Sigma-Aldrich, St. Louis, MO, USA 99.6 C14H10 178.23 
3-Methylphenanthrene 3-MPhe 832-71-3 Larodan Fine Chemicals AB, Sweden 99.9 C15H12 192.26 
2-Methylphenanthrene 2-MPhe 2531-84-2 Sigma-Aldrich, St. Louis, MO, USA 93.8 C15H12 192.26 
2-Methylanthracene 2-MAnt 613-12-7 Koch-Light Laboratories, UK 100 C15H12 192.26 
9-Methylphenanthrene 9-MPhe 883-20-5 Chiron AS, Trondheim, Norway 100 C15H12 192.26 
1-Methylphenanthrene 1-MPhe 832-69-9 Larodan Fine Chemicals AB, Sweden 98.8 C15H12 192.26 
4H-Cyclopenta[def]phenanthrene 4H-CPP 203-64-5 Sigma-Aldrich, St. Louis, MO, USA 99.1 C15H10 190.24 
2-Phenylnaphthalene 2-PN 612-94-2 EGA-Chemie, Steinheim, Germany 94.2 C16H12 204.27 
3,6-Dimethylphenanthrene 3,6-DMPhe 1576-67-6 Larodan Fine Chemicals AB, Sweden 96.1 C16H14 206.28 
3,9-Dimethylphenanthrene 3,9-DMPhe 66291-32-5 Chiron AS, Trondheim, Norway 99.7 C16H14 206.28 
 3 
Fluoranthene Flu 206-44-0 Sigma-Aldrich, St. Louis, MO, USA 97.2 C16H10 202.25 
Pyrene Pyr 129-00-0 Janssen Chimica, Belgium 97.6 C16H10 202.25 
1-Methylfluoranthene 1-MFlu 25889-60-5 Chiron AS, Trondheim, Norway 99.7 C17H12 216.28 
Benzo[a]fluorene B[a]f 238-84-6 Chiron AS, Trondheim, Norway 98.8 C17H12 216.28 
Benzo[b]fluorene B[b]f 243-17-4 Sigma-Aldrich, St. Louis, MO, USA 99.1 C17H12 216.28 
2-Methylpyrene 2-MPyr 3442-78-2 Chiron AS, Trondheim, Norway 98.3 C17H12 216.28 
4-Methylpyrene 4-MPyr 3353-12-6 Chiron AS, Trondheim, Norway 99.6 C17H12 216.28 
1-Methylpyrene 1-MPyr 2381-21-7 Larodan Fine Chemicals AB, Sweden 99.1 C17H12 216.28 
Benzo[ghi]fluoranthene B[ghi]F 203-12-3 Larodan Fine Chemicals AB, Sweden 99.5 C18H10 226.27 
Benzo[c]phenanthrene B[c]Phe 195-19-7 Chiron AS, Trondheim, Norway 99.5 C18H12 228.29 
Benz[a]anthracene B[a]A 56-55-3 Fluka AG, Switzerland 98.4 C18H12 228.29 
3-Methylchrysene 3-MChr 3351-31-3 Chiron AS, Trondheim, Norway 99.1 C19H14 242.31 
2-Methylchrysene 2-MChr 3351-32-4 Chiron AS, Trondheim, Norway 99.7 C19H14 242.31 
6-Methylchrysene 6-MChr 1705-85-7 Chiron AS, Trondheim, Norway 100 C19H14 242.31 
1-Methylchrysene 1-MChr 3351-28-8 Chiron AS, Trondheim, Norway 99.3 C19H14 242.31 
Benzo[b]fluoranthene B[b]F 205-99-2 Chem Service, West Chester, PA, USA 100 C20H12 252.31 
 4 
Benzo[k]fluoranthene B[k]F 207-08-9 Chem Service, West Chester, PA, USA 98.3 C20H12 252.31 
Benzo[e]pyrene B[e]P 192-97-2 Sigma-Aldrich, St. Louis, MO, USA 99.7 C20H12 252.31 
Benzo[a]pyrene B[a]P 50-32-8 Sigma-Aldrich, St. Louis, MO, USA 97.6 C20H12 252.31 
Perylene Per 198-55-0 Sigma-Aldrich, St. Louis, MO, USA 99.5 C20H12 252.31 
Indeno[1,2,3-cd]fluoranthene I[1,2,3-cd]F 193-43-1 
Radiant Dyes, Wermelskirchen, 
Germany 
98.4 C22H12 276.33 
Indeno[1,2,3-cd]pyrene I[1,2,3-cd]P 193-39-5 
AccuStandard Inc., New Haven, CT, 
USA 
99.8 C22H12 276.33 
Dibenz[a,h]anthracene DB[a,h]A 53-70-3 Fluka AG, Switzerland 99.4 C22H14 278.35 
Picene Pic 213-46-7 Larodan Fine Chemicals AB, Sweden 96.1 C22H14 278.35 
Benzo[ghi]perylene B[ghi]p 191-24-2 Janssen Chimica, Belgium 98.8 C22H12 276.33 
Dibenzo[a,l]pyrene DB[a,l]P 191-30-0 
AccuStandard Inc., New Haven, CT, 
USA 
96 C24H14 302.37 
Dibenzo[a,e]pyrene DB[a,e]P 192-65-4 LGC Promochem, Sweden 98 C24H14 302.37 
Coronene Cor 191-07-1 
Radiant Dyes, Wermelskirchen, 
Germany 
100 C24H12 300.35 
Dibenzo[a,i]pyrene DB[a,i]P 189-55-9 Sigma-Aldrich, St. Louis, MO, USA 96.4 C24H14 302.37 
 5 
Dibenzo[a,h]pyrene DB[a,h]P 189-64-0 Koch-Light Laboratories, UK 100 C24H14 302.37 
Phenanthrene-D10 Phe-D10 1517-22-2 Chiron AS, Trondheim, Norway
a
, 
Larodan Fine Chemicals AB, Sweden
b
 
99.3
a
, 
97.2
b
 
C14D10 188.29 
Pyrene-D10 Pyr-D10 1718-52-1 Chiron AS, Trondheim, Norway
a
, 
Larodan Fine Chemicals AB, Sweden
b
 
99.8
a
, 
95.7
b
 
C16D10 212.31 
Benz[a]anthracene-D12 B[a]A-D12 1718-53-2 Chiron AS, Trondheim, Norway 98.6 C18D12 240.36 
Benzo[a]pyrene-D12 B[a]P-D12 63466-71-7 Chiron AS, Trondheim, Norway
a
,  
Larodan Fine Chemicals AB, Sweden
b
 
98.7
a
, 
98.1
b
 
C20D12 264.38 
Benzo[ghi]perylene-D12 B[ghi]p-D12 93951-66-7 Chiron AS, Trondheim, Norway 99.6 C22D12 288.4 
Dibenzo[a,i]pyrene-D14 DB[a,i]P-D14 158776-07-9 LGC Promochem, Sweden 98 C24D14 316.45 
Benzo[a]fluoranthene
c
 B[a]F 203-33-8 Gift from NIST - C20H12 252.31 
Benzo[j]fluoranthene
c
 B[j]F 205-82-3 Larodan Fine Chemicals AB, Sweden 100 C20H12 252.31 
a
 Surrogate internal standard working solution used for sample preparation 22 
b
 Surrogate internal standard used for PAH calibration standard preparation 23 
c
 Not used for quantitation  24 
 6 
S-2. Schematic illustration of the B[a]P-specific online HPLC fractionation system 25 
 26 
Fig. S1. Scheme of the online HPLC fractionation system.  27 
 7 
S-3. Valve positions during a run on the B[a]P-specific online HPLC fractionation system 28 
 29 
Fig. S2. Scheme illustrating the valve positions and flow paths during a run of the B[a]P-specific online HPLC fractionation system: (A)-(C) and (D)-(F) indicate 30 
column flow before and after backflush, respectively. AS: autosampler, V: two position-switching valve, UVD: UV detector, F: fraction, W: waste.  31 
 8 
Table S2. Valve positions during the different steps of a run on the B[a]P-specific online HPLC fractionation system 32 
Time (min) V1 V2 V3 Shown in Figure 
0.00 0 0 0 Fig. S2, A 
6.05
a
 0 0 1 Fig. S2, B 
12.35
b
 0 1 1 Fig. S2, C 
12.85
c
 1 1 1 Fig. S2, D 
13.05
b
 1 0 0 Fig. S2, E 
22.20
a
 1 0 1 Fig. S2, F 
29.20
a
 1 0 0 Fig. S2, A 
30.00 0 0 0 Fig. S2, A 
a
 Adjusted time corrected by adding 0.2 minutes from the observed retention time due to the dead volume after the UV detector 33 
b
 Adjusted backflush time corrected by subtracting 0.05 minutes from the observed retention time due to the time lag of the switching valve 34 
c
 Adjusted time corrected by adding 0.15 minutes from the observed retention time due to the dead volume after the UV detector  35 
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S-4. GC/MS chromatograms of Stockholm air PM extract from the B[a]P-specific online HPLC fractionation system 36 
 37 
Figure S3. GC/MS chromatogram obtained in SIM mode of fraction F1 from an injection of a Stockholm air PM extract on the B[a]P-specific online HPLC 38 
fractionation system. 1: Phe, 2: Ant, 3: 3-MPhe, 4: 2-MPhe, 5: 2-MAnt, 6: 9-MPhe, 7: 1-MPhe, 8: 4H-CPP, 9: 2-PN, 10: 3,6-DMPhe, 11: 3,9-DMPhe, 12: Flu, 39 
13: Pyr, 14: 1-MFlu, 15: B[a]f, 16: B[b]f, 17: 2-MPyr, 18: 4-MPyr, 19: 1-MPyr, 20: B[ghi]F, 21: B[c]Phe, 22: B[a]A, 23: 3-MChr, 24: 2-MChr, 25: 6-MChr, 26: 40 
1-MChr, 27: B[b]F, 28: B[k]F, IS-1: Phe-D10, IS-2: Pyr-D10, IS-3: B[a]A-D12, IS-4:  B[a]P-D12, IS-5: B[ghi]p-D12, IS-6: DB[a,i]P-D14.  41 
 10 
 42 
Figure S4. GC/MS chromatogram obtained in SIM mode of fraction F2 from an injection of a Stockholm air PM extract on the B[a]P-specific online HPLC 43 
fractionation system. 27: B[b]F, 29: B[a]P, IS-1: Phe-D10, IS-2: Pyr-D10, IS-3: B[a]A-D12, IS-4:  B[a]P-D12, IS-5: B[ghi]p-D12, IS-6: DB[a,i]P-D14. 44 
 45 
 46 
Figure S5. GC/MS chromatogram obtained in SIM mode of fraction F3 from an injection of a Stockholm air PM extract on the B[a]P-specific online HPLC 47 
fractionation system. 30: B[e]P, 29: B[a]P, 31: Per, 32: I[1,2,3-cd]F, 33: I[1,2,3-cd]P, 34: DB[a,h]A, 35: Pic, 36: B[ghi]p, 37: DB[a,l]P, 38: DB[a,e]P, 39: Cor, 48 
40: DB[a,i]P, 41: DB[a,h]P, IS-1: Phe-D10, IS-2: Pyr-D10, IS-3: B[a]A-D12, IS-4: B[a]P-D12, IS-5: B[ghi]p-D12, IS-6: DB[a,i]P-D14. 49 
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 50 
Figure S6. GC/MS chromatogram obtained in SIM mode of waste W1 and W2 from an injection of a Stockholm air PM extract on the B[a]P-specific online 51 
HPLC fractionation system. 52 
 12 
S-5. GC/MS chromatograms of blank and hexane injections on the B[a]P-specific online HPLC fractionation system 53 
 54 
Figure S7. GC/MS chromatograms obtained in SIM mode of fractions F1, F2, F3, W1 and W2 from a blank 55 
injection on the B[a]P-specific online HPLC fractionation system. 56 
 13 
 57 
Figure S8. GC/MS chromatograms obtained in SIM mode of fractions F1, F2, F3, W1 and W2 from a hexane 58 
injection on the B[a]P-specific online HPLC fractionation system.  59 
 14 
S-6. GC/MS full scan mass spectra of the system peaks from the B[a]P-specific online HPLC fractionation system 60 
 61 
Figure S9. Full scan mass spectra of system peaks at (A) 29.88 and (B) 30.15 min. 62 
Table S3. Analytical method for the GC/MS analysis 63 
Name Condition 
GC Agilent 6890N (Agilent Technologies, Palo Alto, CA, USA) 
Injection 1 µL, splitless at 300
 C 
Carrier gas He 
Column J & W DB-5ms 30 m × 0.25 mm, 0.25 µm phase 
Oven 60 C for 2 min, 20 C/min to 200 C, 10 C /min to 300 C for 10 min 
MS MSD 5975C (Agilent Technologies, Palo Alto, CA, USA) 
Electron ionization at 70 eV, full scan mode (m/z 50−450), solvent delay 6.00 min, quadrupole at 
150
 C, ion source at 300 C     
 15 
 64 
Figure S10. (A) GC/MS chromatogram of the eluate from the B[a]P-specific online HPLC fractionation system 65 
with (B) full scan mass spectra from each system peak. 66 
 67 
 68 
Figure S11. Stationary phase structure of the PYE column [1].  69 
 16 
S-7. Biological tests of eluates from the B[a]P-specific online HPLC fractionation system 70 
Cell culture and exposure Human hepatocellular carcinoma cells (HepG2) were obtained from the American Type 71 
Culture Collection (Rockville, MD, USA) and cultured as described previously [2]. For cell viability experiments, 72 
cells were seeded at 5 × 10
4
 cells/mL in 24-well plates whereas for Western blot experiments, cells were seeded at 2 73 
× 10
5
 cells/mL in 6-well plates. Cells were cultured for 72 hours, then subsequently exposed to solvent control 74 
(0.1% DMSO), positive control (3 µM B[a]P), or eluates from the HPLC system for 24 hours. Eluates collected 75 
from the B[a]P-specific online HPLC fractionation system were evaporated and re-dissolved in DMSO for the tests. 76 
The same amount of neat hexane was taken and prepared in the same way as method blanks.   77 
Cell viability Cell viability was determined by MTT assay as described previously [2]. Briefly, after exposure 78 
human HepG2 cells were incubated with 0.5 mg/mL MTT for 4 hours, then washed and formazan crystals were 79 
solubilised in DMSO. Optical density was measured at a wavelength of 590 nm. Data are expressed as percentage of 80 
control. 81 
Western blotting Protein levels in cells were determined by Western blotting as described previously [2]. Briefly, 82 
cell protein samples were subjected to SDS-PAGE and thereafter blotted onto PVDF membrane (Bio-Rad, Hercules, 83 
CA). Protein bands were subsequently probed using antibodies. Cell Signaling Technology (Beverly, MA, USA) 84 
provided the following antibodies: Chk1 phosphorylated at Ser317 and H2AX phosphorylated at Ser139. Antibodies 85 
against Cdk2 (M-2), p53 (DO-1) and secondary anti-rabbit and anti-mouse antibodies were obtained from Santa 86 
Cruz Biotechnology (Santa Cruz, CA, USA). Signals were detected using Luminol Western Blotting reagent (Santa 87 
Cruz Biotechnology, Santa Cruz, CA, USA). Densitometric analysis was performed using ImageJ software version 88 
1.48f (National Institute of Health, USA).  89 
 17 
 90 
 91 
 92 
Figure S12. Eluates from the B[a]P-specific online HPLC fractionation system do not induce DNA damage 93 
signalling and are not cytotoxic in HepG2 cells. Phosphorylation of Chk1 at Ser317 (A, B) and H2AX at Ser139 (A, 94 
C) and levels of p53 protein (A, D) were assessed by Western blotting after 24 hours. Cell viability was assessed by 95 
MTT assay after 24 hours (E). Dotted line represents control levels. Experiments were performed in triplicate and 96 
data points represent means ± standard deviations. Where not shown, error lies within the data points. * p < 0.05 as 97 
compared with control levels by one-way repeated measures ANOVA. 98 
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S-8. GC/MS full scan analysis of blank, non-fractionated and fractionated samples 99 
 100 
 101 
Figure S13. GC/MS chromatograms obtained in full scan mode of blank, non-fractionated and fractionated (F1, F2 102 
and F3) samples. 1: B[b]F, 2: B[k]F, 3: B[j]F, 4: B[a]F, 5: Unknown (m/z 268), 6: Unknown (m/z 266), 7: B[e]P, 8: 103 
B[a]P-D12, 9: B[a]P, 10: Unknown (m/z 266), 11: Per. Chromatograms were background subtracted and mass data 104 
was read from the apex of each peak.  105 
 19 
S-9. PAH concentrations in Stockholm air PM sample 106 
Table S4. PAH concentrations (pg/m
3
) in Stockholm air PM sample. Data obtained in the present study is presented 107 
as a mean of three replicates ± standard deviation. 108 
Name Mean ± SD (pg/m
3
) Name Mean ± SD (pg/m
3
) 
Phe 226 ± 3 B[a]A 304 ± 5 
Ant 27.5 ± 0.5 3-MChr 27.1 ± 0.7 
3-MPhe 20.2 ± 0.1 2-MChr 48.2 ± 0.8 
2-MPhe 29.0 ± 0.6 6-MChr 31.7 ± 0.7 
2-MAnt 5.26 ± 0.05 1-MChr 51.2 ± 0.8 
9-MPhe 15.3 ± 0.2 B[b]F 412 ± 7 
1-MPhe 34.5 ± 0.5 B[k]F 204 ± 5 
4H-CPP 41.0 ± 0.1 B[e]P 320 ± 5 
2-PN 26.1 ± 0.4 B[a]P 297 ± 8 
3,6-DMPhe 1.16 ± 0.05 Per 47.6 ± 0.8 
3,9-DMPhe 5.94 ± 0.20 I[1,2,3-cd]F 31.7 ± 0.9 
Flu 345 ± 7 I[1,2,3-cd]P 230 ± 4 
Pyr 390 ± 8 DB[a,h]A 36.7 ± 0.4 
1-MFlu 49.9 ± 1.1 Pic 38.2 ± 0.8 
B[a]f 48.8 ± 0.7 B[ghi]p 352 ± 8 
B[b]f 29.2 ± 0.3 DB[a,l]P 3.07 ± 0.17 
2-MPyr 24.5 ± 0.6 DB[a,e]P 37.5 ± 0.8 
4-MPyr 34.5 ± 0.4 Cor 204 ± 1 
 20 
1-MPyr 40.7 ± 0.3 DB[a,i]P 11.3 ± 0.6 
B[ghi]F 180 ± 5 DB[a,h]P 5.54 ± 0.38 
B[c]Phe 59.8 ± 2.0   
 
 109 
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